Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

Area of Science:

• Immunology
• Cancer Therapy
• Genetic Engineering

Background:

• Natural Killer (NK) cells are crucial for adoptive immunotherapy, especially against tumors with low or absent MHC class I expression.
• However, NK cell efficacy is limited against many solid tumors, including carcinomas and melanoma, even when MHC class I is downregulated.
• Targeting specific tumor antigens is necessary to broaden NK cell applicability.

Purpose of the Study:

• To engineer primary human NK cells to target HER-2, a common antigen on carcinomas.
• To evaluate the in vitro and in vivo efficacy of these modified NK cells against HER-2-expressing tumors.
• To determine if the engineered receptor can overcome inhibitory signals in NK cells.

Main Methods:

• Gene transfer of a chimeric activating receptor specific for HER-2 into primary human NK cells.
• In vitro assessment of NK cell activation (cytokine secretion, degranulation) upon recognition of HER-2 positive tumor cells.
• In vivo efficacy studies using RAG2 knockout mice and HER-2 positive tumors, with tumor eradication visualized by imaging.

Main Results:

• Engineered NK cells showed specific activation against HER-2 positive tumor cells, including autologous targets.
• Activation levels correlated with HER-2 expression on tumor cells.
• Receptor-transduced NK cells demonstrated efficient tumor eradication in vivo, unlike control NK cells.

Conclusions:

• Expression of the HER-2 specific activating receptor overrides inhibitory signals in primary human NK cells.
• Engineered NK cells provide a targeted approach for combating HER-2 expressing carcinomas.
• This strategy holds promise for enhancing NK cell-based cancer immunotherapy.